The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial.
 
Hiromichi Miyagaki
No Relationships to Disclose
 
Masahiro Goto
Honoraria - DAIICHI SANKYO COMPANY,LIMITED; MSD K.K.; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma; Nippon Kayaku; Taiho Pharmaceutical
 
Shunji Endo
Speakers' Bureau - Covidien; JJ Innovative Medicine; Ono Pharmaceutical
Research Funding - Mitsubishi Tanabe Pharma (Inst)
 
Ryo Tanaka
No Relationships to Disclose
 
Takeshi Omori
Honoraria - Daiichi Sankyo
Research Funding - Daiichi Sankyo (Inst)
 
Junji Kawada
No Relationships to Disclose
 
Naoki Takahashi
No Relationships to Disclose
 
Toru Masuzawa
No Relationships to Disclose
 
Haruna Furukawa
No Relationships to Disclose
 
Yuya Sato
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Kazumasa Fujitani
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo; Eisai (Inst); Incyte (Inst); Lilly Japan; Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yukinori Kurokawa
Honoraria - Daiichi Sankyo; Johnson & Johnson; Kaken Pharmaceutical; Lilly; MC Medical; Medtronic; Nippon Kayaku; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Toshimasa Tsujinaka
No Relationships to Disclose
 
Toshio Shimokawa
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)